Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03AGD
|
|||
| Former ID |
DIB019042
|
|||
| Drug Name |
BWA868C
|
|||
| Synonyms |
3-Benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)hydantoin; BW A868C; 118675-50-6; BW-A868C; BW A 868C; BW-A-868C; C25H37N3O5; (+/-)-3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)hydantoin; 4-Imidazolidineheptanoic acid, 3-((2-cyclohexyl-2-hydroxyethyl)amino)-2,5-dioxo-1-(phenylmethyl)-; 4-Imidazolidineheptanoicacid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)-; 3-[(2-Cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)- 4-imidazolidineheptanoic; BWA-868C; BWA 868C; [3H]BWA868C
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C25H37N3O5
|
|||
| Canonical SMILES |
C1CCC(CC1)C(CNN2C(C(=O)N(C2=O)CC3=CC=CC=C3)CCCCCCC(=O)O)O
|
|||
| InChI |
1S/C25H37N3O5/c29-22(20-13-7-4-8-14-20)17-26-28-21(15-9-1-2-10-16-23(30)31)24(32)27(25(28)33)18-19-11-5-3-6-12-19/h3,5-6,11-12,20-22,26,29H,1-2,4,7-10,13-18H2,(H,30,31)
|
|||
| InChIKey |
YZJVWSKJHGEIBL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 118675-50-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7978836, 10239906, 14931487, 29302491, 47285791, 47731162, 48253856, 48253857, 49980272, 53462466, 53788413, 57339908, 85208992, 104414838, 125334179, 135076719, 135650043, 135651140, 143155830, 162250187, 162312826, 163304442, 172918743, 179293737, 201505491, 204378140, 226933504, 252320721, 252457399
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin D2 receptor (PTGDR) | Target Info | Antagonist | [3], [4] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Pathwhiz Pathway | Intracellular Signalling Through PGD2 receptor and Prostaglandin D2 | |||
| Pathway Interaction Database | Thromboxane A2 receptor signaling | |||
| Reactome | Prostanoid ligand receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1899). | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1897). | |||
| REF 3 | Pharmacology and autoradiography of human DP prostanoid receptors using [(3)H]-BWA868C, a DP receptor-selective antagonist radioligand. Br J Pharmacol. 2000 Nov;131(6):1025-38. | |||
| REF 4 | Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998 Apr;123(7):1317-24. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.